下載本文檔
版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAlisporivirCat. No.: HY-12559CAS No.: 254435-95-5Synonyms: DEB-025; Debio-025; UNIL-025分式: CHNO分量: 1216.64作靶點: HCV作通路: Anti-infection儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 100 mg/m
2、L (82.19 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 0.8219 mL 4.1097 mL 8.2194 mL5 mM 0.1644 mL 0.8219 mL 1.6439 mL10 mM 0.0822 mL 0.4110 mL 0.8219 mL請根據產品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內實驗 請根據您的實驗動物和給藥式選擇適當的溶解案,配制前請先配制澄的儲備液,再依次添加助溶劑(為保證實驗結
3、果的可靠性,體內實驗的作液,建議您現現配,當天使;澄的儲備液可以根據儲存條件,適當保存;以下溶劑前的百分指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (2.05 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Alisporivir (DEB-025; Debio-025)親環(huán)蛋抑制劑,具有效的抗丙型肝炎病毒 (HCV
4、) 活性的。體外研究 DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication1. Alisporivir (Debio-025) is an analogue of cyclosporine A and represents the prototype of a new class ofnon-immunosuppressive cyclophilin inhibitors. Alisporivir prevents HCV prote
5、in-mediated collapse of therespiration-driven mitochondrial membrane potential. Alisporivir prevents HCV protein-mediatedmitochondrial dysfunction outside the context of apoptosis, calcium overload, production of ROS, dysfunction2. In cell culture models, low-micromolar doses of alisporivir block SA
6、RS-CoV and MERS-CoV replication.Combination treatment with alisporivir and ribavirin increases the anti-MERS-CoV activity in cell culture 3.Alisporivir pretreatment stimulates antigen presentation by hepatoma target cells, leading to enhancement ofantigen-specific CD8+ T cell activation by 40%. Alis
7、porivir induces an increase of MHC-I and beta-2microglobulin on the surface of several cell lines 4.體內研究 Combination treatment with alisporivir and ribavirin does not protect against SARS-CoV infection in a mousemodel 3.PROTOCOLCell Assay 2 Alisporivir is prepared in DMSO at 4 mM and diluted in cell
8、 culture medium at the indicated concentrations(0.1, 0.2, 0.3, 0.4, 0.5 M). UHCV-32 and UHCVcon-57.3 are U-2 OS human osteosar coma-derived celllines inducibly expressing the entire open reading frame derived from the HCV H77 prototype and consensusclones, respectively. Cell viability is measured by
9、 trypan blue exclusion analysis. HCV protein expression inthese cells is induced by withdrawal of tetracycline from the culture medium. The effect of tetracycline on thenaive U2 OS cell line is tested measuring mitochondria-related respiration and reactive oxygen species(ROS) production, which remai
10、ns unchanged 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Signal. 2019 May 4. pii: S0898-6568(19)30098-1.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Coelmont L, et al. DEB025 (Alisporivir) inhibits hepatitis C virus
11、replication by preventing a cyclophilin A induced cis-trans isomerisationin domain II of NS5A. PLoS One. 2010 Oct 27;5(10):e13687.2. Quarato G, et al. The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction. Hepatology. 2012May;55(5):1333-43.3. de Wilde AH
12、, et al. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in amouse model. Virus Res. 2017 Jan 15;228:7-13.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE4. Esser-Nobis K, et al. The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8(+) T cellactivation. J Hepatol. 2016 Jun;64(6):1305-14.McePdfHeightCaut
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經權益所有人同意不得將文件中的內容挪作商業(yè)或盈利用途。
- 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
- 6. 下載文件中如有侵權或不適當內容,請與我們聯系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2024年新版安置房屋買賣合同示例
- 新興業(yè)態(tài)發(fā)展現狀及趨勢
- 2024年玩具品牌授權銷售合同3篇
- 2024年度索菲亞全屋定制產品銷售合同2篇
- 2024年度軟件許可使用合同標的及相關權利義務詳細說明2篇
- 2024年度商品房認購合同范本(含車位)3篇
- 2024上海住宅小區(qū)消防通道障礙物清除合同參考范本2篇
- 2024年國際專家服務協議標準范本版B版
- 2024年新型砼泵車租賃與施工現場臨時用電合同3篇
- 2024年人力資源獵頭服務全國性企業(yè)人才招聘服務協議3篇
- 乙烯裂解汽油加氫裝置設計
- 計劃分配率和實際分配率_CN
- 小學語文作文技巧六年級寫人文章寫作指導(課堂PPT)
- NLP時間線療法
- JJG596-2012《電子式交流電能表檢定規(guī)程》
- 醫(yī)療質量檢查分析、總結、反饋
- 《APQP培訓資料》
- 通信線路架空光纜通用圖紙指導
- 家具銷售合同,家居訂購訂貨協議A4標準版(精編版)
- 食品加工與保藏課件
- 銅芯聚氯乙烯絕緣聚氯乙烯護套控制電纜檢測報告可修改
評論
0/150
提交評論